Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $150.59 billion. The enterprise value is $199.16 billion.
| Market Cap | 150.59B |
| Enterprise Value | 199.16B |
Important Dates
The last earnings date was Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | May 16, 2025 |
Share Statistics
Amgen has 537.71 million shares outstanding. The number of shares has increased by 0.88% in one year.
| Current Share Class | 537.65M |
| Shares Outstanding | 537.71M |
| Shares Change (YoY) | +0.88% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 78.93% |
| Float | 536.29M |
Valuation Ratios
The trailing PE ratio is 25.59 and the forward PE ratio is 13.54. Amgen's PEG ratio is 2.66.
| PE Ratio | 25.59 |
| Forward PE | 13.54 |
| PS Ratio | 4.41 |
| Forward PS | 4.19 |
| PB Ratio | 24.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.80 |
| P/OCF Ratio | 12.35 |
| PEG Ratio | 2.66 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.66, with an EV/FCF ratio of 18.25.
| EV / Earnings | 33.57 |
| EV / Sales | 5.84 |
| EV / EBITDA | 12.66 |
| EV / EBIT | 19.40 |
| EV / FCF | 18.25 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 9.24.
| Current Ratio | 1.17 |
| Quick Ratio | 0.74 |
| Debt / Equity | 9.24 |
| Debt / EBITDA | 3.60 |
| Debt / FCF | 5.26 |
| Interest Coverage | 2.88 |
Financial Efficiency
Return on equity (ROE) is 105.67% and return on invested capital (ROIC) is 9.67%.
| Return on Equity (ROE) | 105.67% |
| Return on Assets (ROA) | 7.04% |
| Return on Invested Capital (ROIC) | 9.67% |
| Return on Capital Employed (ROCE) | 15.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.37 |
Taxes
In the past 12 months, Amgen has paid $717.00 million in taxes.
| Income Tax | 717.00M |
| Effective Tax Rate | 10.78% |
Stock Price Statistics
The stock price has decreased by -10.12% in the last 52 weeks. The beta is 0.50, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -10.12% |
| 50-Day Moving Average | 300.79 |
| 200-Day Moving Average | 303.44 |
| Relative Strength Index (RSI) | 41.83 |
| Average Volume (20 Days) | 3,163,004 |
Short Selling Information
The latest short interest is 14.54 million, so 2.70% of the outstanding shares have been sold short.
| Short Interest | 14.54M |
| Short Previous Month | 14.08M |
| Short % of Shares Out | 2.70% |
| Short % of Float | 2.71% |
| Short Ratio (days to cover) | 4.28 |
Income Statement
In the last 12 months, Amgen had revenue of $34.13 billion and earned $5.93 billion in profits. Earnings per share was $10.94.
| Revenue | 34.13B |
| Gross Profit | 23.57B |
| Operating Income | 10.27B |
| Pretax Income | n/a |
| Net Income | 5.93B |
| EBITDA | 15.73B |
| EBIT | 10.27B |
| Earnings Per Share (EPS) | $10.94 |
Balance Sheet
The company has $8.81 billion in cash and $57.38 billion in debt, giving a net cash position of -$48.57 billion or -$90.33 per share.
| Cash & Cash Equivalents | 8.81B |
| Total Debt | 57.38B |
| Net Cash | -48.57B |
| Net Cash Per Share | -$90.33 |
| Equity (Book Value) | 6.21B |
| Book Value Per Share | 11.54 |
| Working Capital | 3.92B |
Cash Flow
In the last 12 months, operating cash flow was $12.19 billion and capital expenditures -$1.28 billion, giving a free cash flow of $10.92 billion.
| Operating Cash Flow | 12.19B |
| Capital Expenditures | -1.28B |
| Free Cash Flow | 10.92B |
| FCF Per Share | $20.30 |
Margins
Gross margin is 69.07%, with operating and profit margins of 30.08% and 17.39%.
| Gross Margin | 69.07% |
| Operating Margin | 30.08% |
| Pretax Margin | 19.49% |
| Profit Margin | 17.39% |
| EBITDA Margin | 46.11% |
| EBIT Margin | 30.08% |
| FCF Margin | 31.98% |
Dividends & Yields
This stock pays an annual dividend of $9.52, which amounts to a dividend yield of 3.40%.
| Dividend Per Share | $9.52 |
| Dividend Yield | 3.40% |
| Dividend Growth (YoY) | 5.71% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 87.00% |
| Buyback Yield | -0.88% |
| Shareholder Yield | 2.52% |
| Earnings Yield | 3.94% |
| FCF Yield | 7.25% |
Analyst Forecast
The average price target for Amgen is $323.65, which is 15.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $323.65 |
| Price Target Difference | 15.67% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 2.94% |
| EPS Growth Forecast (5Y) | 26.34% |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.56 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.56 |
| Piotroski F-Score | 6 |